Podcasts about copd

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Top 7 Underrated Supplements Top 7 Underrated Supplements. (1:11) #1 - Vitamin D. (50%) take 2000-4000iu. (2:01) #2 - Vitamin k2. (97%) 100micrograms a day. (8:48) #3 - NAC. 600-1800mgs a day. (11:52) #4 - Berberine. 500mgs 3x day w/food. (13:23) #5 - Glycine. Take before bed on an empty stomach. (15:34) #6 - Choline. 500-2000mgs a day. (17:04) #7 - Grape seed extract. 100-300mgs daily. (21:18) Related Links/Products Mentioned Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! **Code MINDPUMP10 at checkout for 10% off any order. ** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials 97% of Americans are Low In Vitamin K2 Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis Mind Pump #2060: Maximize Fat Loss With Continuous Glucose Monitors: Kara Collier Efficacy of Berberine in Patients with Type 2 Diabetes - PMC The Effects of Glycine on Subjective Daytime Performance in Partially Sleep-Restricted Healthy Volunteers 6 Warning Signs of Choline Deficiency You Must Watch For The impact of grape seed extract treatment on blood pressure changes Visit Legion Athletics for the exclusive offer for Mind Pump listeners! ** Code MINDPUMP for 20% off your first order (new customers) and double rewards points for existing customers. ** Mind Pump Podcast – YouTube Mind Pump Free Resources  

Indianapolis is one of the hotbeds of Histoplasmosis, which is often misdiagnosed and can lead to other health issues throughout the body.  In this episode, you'll learn:—What Histoplasmosis is and the symptoms of it, which "seems like the flu when you get it".  And how "a lot of doctors aren't even aware of it".—The story of how Dr. Prather's own father suffered from COPD as a result of an underlying Histoplasmosis infection he contracted as a kid by being in charge of the chicken coop.—The difficulty in accurately testing for Histoplasmosis, which can be misdiagnosed as Tuberculosis, Lyme Disease, Sarcoidosis, or Macular Degeneration.  And how Histoplasmosis is "the number one cause of blindness in Indiana".—How Antibiotics and Steroids that are often prescribed by doctors will actually make the Histoplasmosis "take off" and become "systemic".—Why Indianapolis is such a center for Histoplasmosis outbreaks.  And why Dr. Prather says that everyone who has lived in the area for 5 years has Histoplasmosis.—The natural products Dr. Prather has found to be even more effective for Histoplasmosis than prescription drugs because they actually rebuild the body's immune system.  And why Dr. Prather says "the strongest anti-fungal medicine known to man" is Oregano Oil.—The importance of Homeopathy, which Dr. Prather says has made a big difference in "the real serious cases" of Histoplasmosis.  And why Dr. Prather says "you are going to have problems" if your Vitamin D and Vitamin A are low. —How a weakened immune system, nutritional deficiency, or stress are usually the reasons that a Histoplasmosis infection takes off in the first place.  And how you probably have a secondary Histoplasmosis infection that needs to be addressed if you live in Indianapolis and have Long COVID.—Why Chiropractic, Acupuncture, and Diathermy are helpful for Histoplasmosis.  And the Spleen-21 Acupuncture point that causes people to feel immediately better when they are sick.—How Dr. Prather has had patients suffering from Kidney failure and patients dealing with Hypertension whose real underlying issue was Histoplasmosis.http://www.TheVoiceOfHealthRadio.com

Story at-a-glance Chronic respiratory diseases remain profitable but poorly treated, subjecting patients to expensive healthcare, impaired stamina, and painful decline DMSO is an "umbrella remedy" treating diverse ailments through therapeutic properties including reducing inflammation, improving circulation, and reviving dying cells These properties uniquely address underlying causes of chronic respiratory diseases by reducing fibrosis and inflammation, restoring damaged organs, and improving circulation DMSO addresses respiratory infections through antimicrobial activity, reduced lung inflammation, and potentiation of antimicrobial therapies Extensive published data and user reports demonstrate DMSO's remarkable results for asthma, COPD, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and pneumonia, including cases in which transplant was no longer necessary due to significant organ recovery

Send Audrey a Text to get your question answered on the showAs requested, here is the episode on Heaves, also known as RAO, COPD, and IAD. What do all of these have in common? A base in allergies. In this episode we are talking about:Calling your vet. Breathing issues are no joke and there are other more serious conditions to rule out.Nutritional support, where to start, what to change from the base anti-inflammatory forage diet.Herbal support - individual herbs to try and my favorite blended pre-made productsHomeopathy - supporting constitutionally, with nosodes, and symptom support Find all the Resource Listed Here: linktr.ee/equineenergymed Audrey is not an MD or DVM and has never implied or claimed to be either. Audrey holds a Doctoral Degree of Traditional Naturopathy and a Masters Degree in Science. She created an evidenced-based anti-inflammatory nutrition program for equine and has successfully helped over 10k horses. This information is not meant to diagnose, prescribe for, treat, or cure, and is not a replacement for your veterinarian. These are my personal interpretations based on my education, skill and clinical experience.

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today, we're focusing on an often-overlooked peptide called VIP, short for Vasoactive Intestinal Peptide. The name might sound technical, but this peptide plays some important roles in the body. It helps regulate inflammation, supports nerve function, improves blood flow by relaxing blood vessels, and may even have benefits for things like chronic pain, including back pain. Let's get into it. What is VIP? We've talked about VIP before on a previous podcast, but it's been awhile and I'd like to start with the basics as a refresher.  VIP is a 28-amino acid neuropeptide that acts like a signaling molecule in both the central and peripheral nervous systems. Think of it like a chemical messenger that can influence a lot of different body systems. VIP belongs to the glucagon/secretin peptide superfamily, and it's found throughout the body, including your brain, intestines, lungs, and immune cells. Now, what does VIP actually do? Well it does quite a bit. VIP works by binding to specific receptors on cells—called VPAC1 and VPAC2—which trigger a chain reaction inside the body through something known as the cyclic AMP pathway. Once activated:  It relaxes smooth muscles, which helps open up blood vessels (vasodilation) and airways (bronchodilation) It stimulates secretion of water and electrolytes in places like the gut and pancreas—so yes, it helps with digestion too It's a major immune modulator, calming inflammation by regulating immune cell behavior  Neuroprotective role, supporting the survival and adaptability of neurons VIP in Medicine – What's the Buzz? VIP has been studied in a variety of conditions. Inflammatory diseases like rheumatoid arthritis and Crohn's Neurodegenerative conditions like Alzheimer's and Parkinson's Autoimmune diseases like osteoarthritis Respiratory conditions like pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD) or due to mold toxicity But today, we're zooming in on something more tangible for a lot of people—back pain. VIP and Back Pain – What Do We Know? Let's get into the science here. VIP has recently caught attention for its potential role in intervertebral disc degeneration, which is one of the top causes of chronic low back pain. A 2024 study found that VIP receptors were significantly reduced in degenerated human discs—which is kind of a red flag. When VIP was given to mice for four weeks, researchers saw slowed degeneration, better structural proteins like aggrecan, and overall healthier discs on imaging. Promising, right? But here's the catch—this was a preclinical animal study. We still need human trials to confirm it works outside the lab. VIP and Joint Pain And when it comes to VIP and joint pain, there's a bit more research on VIP and osteoarthritis, especially when the spine is involved. In OA models, VIP was shown to lower pro-inflammatory cytokines—those molecules that contribute to pain and make joints hurt. But here's where it gets complicated: some studies report that VIP accumulation in joints might actually worsen pain. So... it's a bit of a paradox. So what's the takeaway? VIP can be helpful—but its role in pain management seems to depend on how much, where, and what kind of pain we're talking about. VIP in Peptide Therapy – Real-World Use? In peptide clinics—especially those using integrative or regenerative medicine approaches—VIP is sometimes part of treatment protocols for nerve-related pain and inflammation. It's often paired with other peptides like BPC-157 and TB-500. You can find some clinics that list VIP as a go-to for chronic pain, including back pain. But here's the reality check, clinical data is limited, success is anecdotal, it's pricey and results can vary from person to person. So while VIP might help reduce inflammation and slow tissue degeneration, it's not a substitute for tried-and-true pain management peptides like BPC-157. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

In the first episode of our Rare Lung Diseases podcast series, host Saranya Ravindran speaks with James Stoller, Chief of Education and Pulmonary Physician at Cleveland Clinic, about Alpha-1 antitrypsin deficiency, a rare genetic condition that is frequently underdiagnosed. The discussion explores the complexities of Alpha 1, including current challenges in detection, advances in diagnosis and management, and what the future may hold for improving care. Timestamps: 1:20 - Current barriers to timely diagnosis 4:35 - How close are we to identifying all patients with Alpha 1? 5:20 - Role of consumer genomics in alpha detection 6:20 – Targeted testing amongst COPD patients

In this inspiring episode of the She Built It® Podcast, host Melanie Barr speaks with inventor and tech entrepreneur Sharon Samjitsingh, co-founder and CEO of Health Care Originals. Driven by her lifelong struggle with asthma, Sharon shares how her personal story and professional expertise in innovation led her to build life-changing wearable tech that helps people with chronic respiratory diseases. She opens up about the emotional toll of asthma, the importance of first-principles thinking, and her journey as a woman innovating in deep tech. Sharon's story is one of resilience, passion, and purpose—and a reminder that when you can't breathe, nothing else matters.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

The Good News That Media Doesn't Tell You Before diving into the political chaos, we start with hope: 3D-printed lung tissue that could cure COPD and asthma, revolutionary IVF techniques saving babies from mitochondrial diseases, and breakthrough infant heart transplant procedures expanding donor pools by 20%. Sometimes the best news is the news that reminds us human ingenuity is solving problems we thought impossible. Congressional Chaos & Crypto Drama The Senate passes Trump's $9 billion spending cuts in a nail-biter 51-48 vote, targeting foreign aid and public broadcasting. But the real drama? House Republicans initially blocked crypto bills during "Crypto Week" until Trump personally called holdouts to the Oval Office. We break down the GENIUS Act for stablecoin regulation, Bitcoin hitting $123K, and why regulating an industry you're profiting from might be problematic. The Musk vs. Trump Epstein Files Showdown Elon Musk has gone full chaos mode against Trump over Jeffrey Epstein files, even announcing an "America Party" to prioritize their release. We explore how this billionaire Twitter beef is creating genuine fractures in the MAGA movement and potentially costing Republicans seats in 2026. Immigration Crackdown Reality Check ICE now has access to 79 million Medicaid enrollees' personal data for deportation efforts. We examine the surge in arrests (47% without criminal charges), violent California cannabis farm raids, and the controversial "Alligator Alcatraz" detention center that Democrats and Republicans describe completely differently. International Military Escalation Trump's "Operation Midnight Hammer" strikes on Iranian nuclear facilities, his complete flip on Russia policy with 100% tariff threats, and renewed violence in Syria. Plus, the ongoing Gaza humanitarian crisis and why a 20-year-old American was allegedly killed by Israeli settlers in the West Bank. Research on a Dime: What Is Socialism Actually? We break down the most misunderstood political term in America. Spoiler alert: Those "socialist" Nordic countries? Not actually socialist. Denmark's PM had to literally tell Americans to stop calling them that. We explore real socialism's pros and cons, why Americans already live with tons of "socialist" policies, and what NYC mayoral candidate Zohran Mamdani's democratic socialism experiment might mean for American politics. Domestic Policy Pandemonium Trump freezes $6 billion in education grants, threatens to strip citizenship from political opponents (spoiler: he legally can't), and escalates tariffs on 100+ countries while inflation ticks upward. We also cover the Texas flooding tragedy, church shooting in Kentucky, and why your medical debt might stay on your credit report after all. The Numbers That Matter Bitcoin: $123,165 all-time high ICE arrests: 930 daily (triple the original target) Immigration detention: 60,000 people (20,000 over Congressional funding) Texas flooding: 80+ dead, 41 still missing Gaza casualties: 57,000+ Palestinians killed since October 7, 2023 Purple Political Breakdown cuts through partisan noise to deliver nuanced analysis of the week's biggest political stories. We explain complex policies, decode political theater, and research topics that actually matter all while maintaining our commitment to balanced, fact-based journalism that treats our audience like adults capable of forming their own opinions. Subscribe for weekly episodes breaking down the political stories that shape America, without the partisan spin.Standard Resource Links & RecommendationsThe following organizations and platforms represent valuable resources for balanced political discourse and democratic participation: PODCAST NETWORKALIVE Podcast Network - Check out the ALIVE Network where you can catch a lot of great podcasts like my own, led by amazing Black voices. Link: https://alivepodcastnetwork.com/ CONVERSATION PLATFORMSHeadOn - A platform for contentious yet productive conversations. It's a place for hosted and unguided conversations where you can grow a following and enhance your conversations with AI features. Link: https://app.headon.ai/Living Room Conversations - Building bridges through meaningful dialogue across political divides. Link: https://livingroomconversations.org/ BALANCED NEWS & INFORMATIONOtherWeb - An AI-based platform that filters news without paywalls, clickbait, or junk, helping you access diverse, unbiased content. Link: https://otherweb.com/ VOTING REFORM & DEMOCRACYEqual Vote Coalition & STAR Voting - Advocating for voting methods that ensure every vote counts equally, eliminating wasted votes and strategic voting. Link: https://www.equal.vote/starFuture is Now Coalition (FiNC) - A grassroots movement working to restore democracy through transparency, accountability, and innovative technology while empowering citizens and transforming American political discourse FutureisFutureis. Link: https://futureis.org/ POLITICAL ENGAGEMENTIndependent Center - Resources for independent political thinking and civic engagement. Link: https://www.independentcenter.org/ Get Daily News: Text 844-406-INFO (844-406-4636) with code "purple" to receive quick, unbiased, factual news delivered to your phone every morning via Informed ( https://informed.now) All Links: https://linktr.ee/purplepoliticalbreakdownThe Purple Political Breakdown is committed to fostering productive political dialogue that transcends partisan divides. We believe in the power of conversation, balanced information, and democratic participation to build a stronger society. Our mission: "Political solutions without political bias."Subscribe, rate, and share if you believe in purple politics - where we find common ground in the middle!

On this episode of Vitality Radio, Jared welcomes back naturopathic physician Dr. Lexi Loch from Terry Naturally to uncover two of the most powerful herbs in natural medicine: Boswellia and Curcumin (from Turmeric). While many are familiar with turmeric for inflammation, few realize that Boswellia (also known as frankincense) targets a completely different inflammatory pathway—one that traditional NSAIDs and pain relievers don't touch. Together, these herbs form a potent, well-researched duo for addressing pain and inflammation in the gut, joints, lungs, and beyond. You'll learn about the unique pathway that Boswellia modulates, the advantages of this unique curcumin extract over conventional turmeric extracts, and how combining the two offers faster and longer-lasting support. Whether you're struggling with IBS, asthma, joint pain, or simply want to manage everyday inflammation more naturally, this episode provides evidence-based insight and practical guidance you can trust.Products:Terry Naturally Boswellia & Curcumin ProductsAdditional Information:#524: Maximum Absorption of Nutrients for Energy, Pain, Immune, and Respiratory Challenges with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Dr. Paul will share updates with regard to COPD management including genetics, lung cancer screening and non-prescription treatment options.

Send us a textDr. Marc Salzberg, MD is President, Chief Executive Officer & Chief Medical Officer of Airway Therapeutics ( https://www.airwaytherapeutics.com/ ), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.Dr. Salzberg has more than 25 years of academic and pharmaceutical experience in the management of drug development and clinical research, including medical management of anti-viral drugs clinical development and market introduction including saquinavir and ganciclovir. He spent several years at Roche's headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC).During his career, Dr. Salzberg has successfully managed the growth and acquisition of two contract research organizations benefitting shareholders. He was a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under his leadership. He then served as Vice President of Medical Affairs at Medpace.Dr. Salzberg earned his Medical Doctorate degree from the University of Basel, Switzerland. His medical training and practice include pediatrics/ neonatology and oncology.#MarcSalzberg #AirwayTherapeutics #HumanSurfactantProteinD #Collectin #PathogenRecognition #RespiratoryDiseases  #InflammatoryResponse #BronchopulmonaryDysplasia #ZelpultideAlfa #Covid #Asthma #COPD #Influenza #RSV #ARDS #AcuteRespiratoryDistressSyndrome #ChronicObstructivePulmonaryDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

#181: Death doesn't have to be a cold, clinical experience tucked away in hospital corners. Yet the word "hospice" still strikes fear in the hearts of so many, often because we fundamentally misunderstand what hospice truly offers.In this profound conversation with Karissa, a veteran hospice nurse with eight years of experience across four different states, we peel back the layers of misconception surrounding end-of-life care. "If death is inevitable, it matters where and when and how," she explains, challenging our cultural tendency to avoid these conversations until it's often too late.What exactly happens when hospice steps in? Far from being just for the imminently dying, hospice provides comprehensive support for both patients and families, sometimes for years rather than days. Karissa walks us through the full spectrum of resources available – from 24/7 nursing support and equipment to spiritual care and family counseling – all covered 100% by Medicare and Medicaid. We explore the telltale signs that it might be time to consider hospice for conditions like CHF, COPD, Alzheimer's, and cancer, and why waiting too long often leads to preventable suffering.Perhaps most beautifully, Karissa describes her role as "midwifery for the dying," drawing a powerful parallel between how we usher life into this world and how we can compassionately guide it out. Whether you're a healthcare provider hesitant to broach this topic with patients, a family member wondering if it's time to consider additional support, or simply someone wanting to understand this inevitable part of the human experience, this episode offers practical wisdom, honest insights, and unexpected moments of lightness in what's typically considered a heavy subject. Listen, share, and join the conversation about making the end of life as meaningful and comfortable as possible.You can now send us a text to ask a question or review the show. We would love to hear from you! Follow me on social: https://www.instagram.com/babbles_nonsense/

What is the environmental impact of respiratory illness? Find out in this episode of the EMJ GOLD podcast, where Shish Patel, Medical Director, Chiesi UK, joins Isabel to discuss the rising burden of COPD and the impact of respiratory care on the planet.  Together, the two explore the diagnostic gap in COPD, improving the experience of people living with the disease, balancing health innovation with climate concerns and much more.   A little more on EMJ GOLD's guest…  Shish Patel trained as a pharmacist and has worked in the pharmaceutical industry for over 30 years. Currently, he serves as Medical Director at Chiesi UK and Ireland, and he has held senior positions within medical and scientific functions at both affiliate and global level throughout his career. In addition to his significant time at Chiesi, Shish has held positions at GSK and Sanofi. Shish also holds key industry board positions including at the Prescription Medicines Code of Practice Authority and the ABPI.   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-441 Overview: Explore the evidence behind inspiratory and expiratory strength training to improve sleep quality, reduce daytime fatigue, ease COPD symptoms, and lower blood pressure. This episode offers practical guidance on how you can integrate this simple, affordable intervention to support better breathing and overall health in your patients. Episode resource links: OSA: Journal of Sleep Research. 2024;33(3):e13941. doi:10.1111/jsr.13941. Sleep & Breathing = Schlaf & Atmung. 2022;26(4):1527-1537. doi:10.1007/s11325-021-02536-4. HTN: Journal of Applied Physiology (Bethesda, Md. : 1985). 2020;129(3):449-458. doi:10.1152/japplphysiol.00024.2020. COPD: Chest. 2003;124(4):1357-64. doi:10.1378/chest.124.4.1357. Sleep: Sleep. 2016;39(6):1179-85. doi:10.5665/sleep.5826. Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-441 Overview: Explore the evidence behind inspiratory and expiratory strength training to improve sleep quality, reduce daytime fatigue, ease COPD symptoms, and lower blood pressure. This episode offers practical guidance on how you can integrate this simple, affordable intervention to support better breathing and overall health in your patients. Episode resource links: OSA: Journal of Sleep Research. 2024;33(3):e13941. doi:10.1111/jsr.13941. Sleep & Breathing = Schlaf & Atmung. 2022;26(4):1527-1537. doi:10.1007/s11325-021-02536-4. HTN: Journal of Applied Physiology (Bethesda, Md. : 1985). 2020;129(3):449-458. doi:10.1152/japplphysiol.00024.2020. COPD: Chest. 2003;124(4):1357-64. doi:10.1378/chest.124.4.1357. Sleep: Sleep. 2016;39(6):1179-85. doi:10.5665/sleep.5826. Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck recently made a significant move in the pharmaceutical industry by acquiring Verona for $10 billion, gaining access to the commercial COPD drug Ohtuvayre. This acquisition is viewed as a strategic decision to offset potential revenue loss when the patent for Keytruda expires. In other news, the Supreme Court has suspended an injunction preventing RFK Jr.'s HHS cuts. AstraZeneca also finalized a deal with JCR worth up to $825 million for gene therapy AAVs. Additionally, Trump has threatened 200% pharma tariffs, but has provided a one-year grace period for implementation. Drug developers are being advised to digitize their outsourcing path for optimal success in the industry. Furthermore, Novo Nordisk has terminated a deal with Hims & Hers, while Lilly has received an FDA label update for an Alzheimer's drug. Various developments in the longevity biotech space have also been highlighted. Stay tuned for more updates in the pharmaceutical industry.

We sit down with three distinguished endocrinologists—Dr. Kashif Latif, Dr. Michael James Haller, and Dr. Kevin Kaiserman—to discuss the last 100 years of innovation in diabetes treatment, from starvation diets to modern insulin therapy.  In this episode, we discuss FDA and non-FDA-approved interventions in medical science. Please do not rely on this podcast for medical advice or as a guide for prescribing. The following were mentioned on the podcast, and you should be aware of their side effects and complete indications as prescribed by the FDA.As with any treatment, it's important to understand the potential adverse reactions with TZIELD. Throughout the TN-10 Study, greater incidences of cytokine release syndrome, serious infections, hypersensitivity reactions, and serum sickness, lymphopenia, and neutropenia were reported in TZIELD-treated patients vs placebo-treated patients. Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache. These are not all the adverse reactions reported with TZIELD. Please see full Important Safety Information and Prescribing Information.AFREZZA can cause serious side effects, including: Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, consult your healthcare clinician.Inhale Study Link 01:25 Early Screening and Universal Screening02:18 Dr. Latif's Journey into Endocrinology04:22 Dr. Haller's Path to Pediatric Endocrinology05:09 Dr. Kaiserman's Career in Diabetes Care05:54 The Importance of EHR in Diabetes Management08:21 Project ECHO: Extending Community Health Outcomes15:39 The Evolution of Insulin Therapy24:22 Revolutionizing Diabetes Care with Inhaled Insulin28:19 Refrigeration and Stability of Insulin28:43 Human Insulin and Genetic Engineering30:04 Inhaled Insulin vs. Insulin Pumps31:33 Inhaled Insulin for Type 2 Diabetics32:28 Challenges in Managing Type 1 Diabetes36:23 Preventing and Delaying Insulin Dependency38:53 The Importance of Early Screening50:14 Future of Type 1 Diabetes TreatmentSupport the show

In this episode of Inside Startup Investing, Chris Lustrino interviews Sharon Samjitsingh, co-founder and CEO of Health Care Originals, a respiratory health startup using wearable technology and predictive AI to help asthma and COPD patients avoid flare-ups before they happen.Sharon shares her personal journey as an asthma patient and how that experience — paired with her background managing $150M+ in innovation deployments — led her to build a platform now supported by independently validated clinical results, $5.8M in ARR contracts, and a waitlist of 12,000+ patients. Founders will learn how to productize deep tech, unlock B2B2C healthcare sales, and design for scale in a hardware-software business model.Highlights include…Founder story: From chemical engineer to patient-turned-healthtech CEO (1:50)Product overview: Wearable + AI + coaching + environmental support (5:32)Predicting asthma attacks 3 months in advance (6:57)How to turn sensor data into behavior change, not just alerts (8:48)Proving outcomes: Clinical results, validation, and third-party guarantees (11:08)

Gas cookers are a common feature in many kitchens, often preferred by chefs and home cooks for their precise temperature control but gas cookers emit a number of harmful substances when they are in use and even when they are off that can pollute the indoor air and harm your health. Nitrogen dioxide, or NO2, is a gas that is produced when natural gas is burned at high temperatures. It can damage your airways and worsen asthma and COPD. A recent report by the Dutch Lung Foundation found that gas cookers increased the risk of asthma in children by 42%. What are some other of these pollutants and their effects? And what can you do to reduce these risks? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠Is there any truth that lemon water is good for you ?⁠ ⁠Why do we get great ideas in the shower?⁠ ⁠Should I cut the electricity at home during a storm?⁠ A podcast written and realised by Amber Minogue. First Broadcast: 2/11/2024 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast accompanying the July issue of DTB  (https://dtb.bmj.com/content/63/7), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss the editorial (https://dtb.bmj.com/content/63/7/98) which focuses on some key changes in the new national asthma guideline and the implications for patients and healthcare professionals. A DTB Select article (https://dtb.bmj.com/content/63/7/99) provides an overview of a double-blind randomised placebo-controlled trial that assessed whether bisoprolol reduced the number of exacerbations in people with COPD. The main article (https://dtb.bmj.com/content/63/7/103) is an overview of abaloparatide, which is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.   The podcast begins with a discussion about ideas for new articles for DTB and the therapeutic areas currently under consideration. If you have a suggestion for an article that you would like DTB to cover, please email details to dtb@bmj.com.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

People with lung conditions like asthma or chronic obstructive pulmonary disease, abbreviated COPD, rely on air conditioning in the summer to help keep their symptoms from getting much worse. William Checkley, a lung health expert at Johns Hopkins, says it's … If you don't use AC properly you may make lung problems worse, Elizabeth Tracey reports Read More »

Substack is where I discovered Dr. MeiLan Han! I was browsing through and was pleasantly surprised to read an article, and learn that she wrote a book called, Breathing Lessons. And to top it off, she's from my home state of Michigan. I also learned the Dr. Han's book was “a passion project during the pandemic.”I'm delighted to share a conversation with Dr. MeiLan Han, one of the country's most respected voices in lung health and a tireless advocate for people living with chronic respiratory conditions.Dr. Han is a Professor of Medicine and Chief of Pulmonary and Critical Care at University of Michigan Health. She's not only cared for patients at the bedside but has devoted her career to understanding lung disease at its roots, with a special focus on chronic obstructive pulmonary disease (COPD), a condition that remains widely under-recognized and underfunded. Through her research, Dr. Han is helping to uncover how diseases like COPD affect the lungs in different ways, with the goal of making treatment more precise, more effective, and more personalized.Her journey began at the University of Washington and continued through specialized training at the University of Michigan, where she also earned a Master's degree in Biostatistics and Clinical Study Design. Today, she leads research funded by the National Institutes of Health (NIH), serves on national advisory boards for the COPD Foundation and the American Lung Association, and contributes to global guidelines that shape how lung disease is diagnosed and treated.Dr. Han also serves as Deputy Editor of the American Journal of Respiratory and Critical Care Medicine, helping to guide the direction of clinical practice and research in pulmonary medicine.If you or someone you love is living with a chronic lung condition, Dr. Han's insight is not only encouraging, it's essential. I'm so grateful to bring her voice to this platform. How many breathes do we take in a lifetime? It's fascinating to discuss and you'll hear the answer in our podcast.Lung health, do you think about it?To get her book: https://www.amazon.com/Breathing-Lessons-Doctors-Guide-Health-ebook/dp/B08X2ZFGNZ/ref=tmm_kin_swatch_0 Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Send us a textIn this podcast episode, we explore groundbreaking research presented at the ISTH 2025 in Washington. Dr. Vicky May, Institut Universitaire de Cardiologie et Pneumologie de Québec, shares insights into a new diagnostic algorithm for pulmonary embolism (PE) in patients with chronic obstructive pulmonary disease (COPD). Her work focuses on identifying specific predictors, integrating these with established testing methods, and addressing challenges in the validation process. The discussion also highlights a study on recurrent venous thromboembolism (VTE), emphasizing symptom patterns and recurrence likelihood. These findings aim to refine clinical diagnostics, offering physicians refined tools for better patient management in thrombosis-related conditions.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this enlightening episode, Amb. Elisha sits down with Eric J. Klos, visionary founder of Daily Breath, to explore how environmental factors—especially air quality—directly impact our health.   With over a decade of pioneering work in environmental health and respiratory research, Eric shares the story behind his groundbreaking app that empowers users to track symptoms, identify environmental triggers, and take proactive action for better health.   You'll discover:   • The link between air quality and chronic conditions like asthma, COPD, and even neurological diseases.   • How climate change and extreme weather events are accelerating health risks through allergens, pollutants, and mold.   • Why wearable air monitors and personalized data are the future of preventative healthcare.   • How Daily Breath helps you track your unique health responses to the air you breathe—daily.   Whether you're a health-conscious individual, medical professional, or climate advocate, this conversation offers profound insight into the future of health and environmental tech.   Reach Eric:  https://urlgeni.us/dailybreathapp ... Want to be a guest on WITneSSes? Send Elisha Arowojobe a message on #PodMatch, here: https://www.podmatch.com/member/ambelisha     Elevate your business with Anastasia's expert consulting. Use code Elisha3 for an exclusive offer and transform your business today! https://resurrectionmentor.wixsite.com/so/42PDEPEB8?languageTag=en   Feel like something's missing? Start Living the Magical Life today. Buy Now: https://a.co/d/4sHrFx2   Amb. Elisha just published a transformational workbook, buy now: https://ambelisha.gumroad.com/l/Llaenlap

We love to hear from our listeners. Send us a message. On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations. This episode of the Business of Biotech is brought to you by Ecolab.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

06/22/25The Healthy Matters PodcastS04_E18 - The ABCs of COPDWith Special Guest:  Dr. Caroline Davis, MDDid you know that 6.5% of Americans have physician-diagnosed Chronic Obstructive Pulmonary Disease (COPD)?  That's a pretty staggering statistic...  You might think that people get it from smoking, and well, you'd be right.  But that's not the only thing that can cause it!  COPD is a disease of the airways where people have difficulty getting air out  of there lungs.  But why is that an issue?  Who's most likely to be afflicted with this condition?  And best yet, how can you avoid it altogether?Joining us on Episode 18 of our show is Dr. Caroline Davis, a pulmonologist at Hennepin Healthcare, and just the expert to help us get to the bottom of some of these questions.  We'll go over the common causes of COPD, who's at risk, the current and future treatments available, and how this condition differs from other afflictions, like emphysema and asthma.  COPD can be a serious disease, but there are a lot great treatments available, and believe us when we say that at the end of this episode, you'll be breathing a little easier.  Join us!We're open to your comments or ideas for future shows!Email - healthymatters@hcmed.orgCall - 612-873-TALK (8255)Get a preview of upcoming shows on social media and find out more about our show at www.healthymatters.org.

Thanks for listening!

Sly & The Family Stone's frontman Sly Stone (Sylvester Stewart), died 6/9 from COPD. Hulu premiered his Sly Lives documentary in February for Black History Month. Going from church, radio, producing, fame, and downfall, he innovated multiple genre's future sounds. I discuss Sly's bio and created a playlist for you to hear his influential sounds by other artists. Theme Song: "Dance Track", composed by Jessica Ann CatenaMusic Catalog / YouTube ChannelEpisode PlaylistMedia Mentioned: Uncle Buck Dance Scene (1989), Summer of Soul, 50 Years of SNL Music,Rock Talk StudioSongs Mentioned: "Laugh, Laugh" - The Beau Brummels (1965)"Somebody to Love" - Jefferson Airplane! (1967)"Hot Fun in the Summertime" - David T. Walker (1971), The Beach Boys (1992), The Manhattan Transfer & Chaka Khan (1995)"People Everyday" - Arrested Development (1992)"Stand" - Lenny Kravitz (2011) - live"Rhythm Nation" (1989-1990), "And On And On" (1993-1994) - Janet Jackson"Mama Said Knock You Out" - LL Cool J (1990-1991)"Fight the Power" - Public Enemy (1989)"Star/Pointro" - The Roots (2004)"Boogie Shoes" - KC and the Sunshine Band (1975)"Shadrach" - Beastie Boys (1989)"Weapon of Choice" - Fatboy Slim & Bootsy Collins (2000)"No One to Depend On" - Santana (1971)"Rocky Mountain Way" - Joe Walsh (1973)"X-tasy" - Missy Elliott (2001)"Love and Happiness" - Al Green (1972, 1977); BET Awards 2008Related Episodes: Ep. 37 - 20 Summer Songs CountdownEp. 120 - That's My Jam - Game ShowEp. 154 - Janet Jackson's Rhythm NationEp. 220 - Top 40 Songs of 2023 (Part 1)Ep. 241 - The Beach Boys Rare 10Ep. 272 - Top 40 Songs of 2024 (Part 1)

Pomegranates are put to the test for weight loss, diabetes, COPD, prostate cancer, osteoarthritis, and rheumatoid arthritis.

Sharon Samjitsingh is an asthma patient and developer of the ADAMM wearable device and Nightingale emergency respiratory care services. She has suffered with asthma her entire life and as a child, fear surrounded her and her family never knowing when the next attack would occur. As an adult she decided to do something to help others monitoring their breathing rhythms, heart rate and symptoms by developing a wearable technology that is taped under the torso and data relayed to a smartphone or computer via wifi that send alerts of an upcoming attack far in advance of its presentation. Her team of on call respiratory therapists then coach the patient with breathing education and behavior modification to reduce likelihood of presentation of an attack. Her results have changed the life of an asthma, COPD, ILD, and Cystic Fibrosis patient from a life caged by fear to one of empowering freedom and self-control. For review of the studies, visit healthcareoriginals.com

This week, join Kate, Mark and Henry as they discuss all in one triple inhalers for COPD, the best medication for pain management in children and suzetrigine, a new medicine for acute pain in adults. Gary is off this week, working on his French lessons. And we add intro music! Yay!

Maria Artunduaga is the founder & CEO of Samay, the winner of the 2024 MedTech Innovator accelerator, as well as a groundbreaking physician, scientist, and inventor. Maria discusses her inspiring journey from a small town in Columbia to leading a top MedTech company in the US. After pivoting away from plastic surgery training, she channeled her efforts into creating Sylvee, an AI wearable sensor for COPD patients. Maria shares her relentless determination, innovative problem-solving strategies, and the creation of a company culture that emphasizes learning and diversity.    Guest links: https://www.samayhealth.com/home | https://www.linkedin.com/in/drartunduaga/  Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 057 - Maria Artunduaga [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and I am delighted to welcome as my guest today, Maria Artunduaga. Maria is a physician, scientist, and inventor with 60 plus prizes, including becoming the first woman to lead a US LATAM company to win MedTech Innovator, the world's most competitive accelerator for medical technology surpassing over 1300 global companies. A top 1% student in Columbia, her country of birth, she relocated to the US to pursue plastic surgery training, but abandoned it to dedicate herself to solve the problem that killed her grandmother-- a lack of home technologies that can detect COPD exasperations early. Maria has raised 5.2 million, almost 60% in non-dilutive capital from NSF and NIH to build Sylvee, an AI wearable sensor that can provide COPD patients with continuous data on pulmonary functions similar to what continuous glucose monitoring sensors do for diabetic patients. Her invention has been featured by a hundred plus media outlets, including Forbes, TechCrunch, Bloomberg, Fierce Healthcare, and more. Before Samay, Maria completed postdoctoral studies in human genetics at Harvard Medical School, started a plastic surgery residency at the University of Chicago, and completed two master's degrees, one in global public health at the University of Washington, and another in translational medicine at the University of California at Berkeley and San Francisco. She lives in Mountain View, California with her husband, 2-year-old daughter, and four pets. In her free time, she enjoys flamenco dancing, bolero singing, traveling the world, and fostering diversity in and outside the workplace by mentoring underrepresented scientists and entrepreneurs. All right. Well, thank you so much for being here, Maria. I'm so excited to finally get a chance to speak with you. I'd love if you would share a little bit about your background and your career trajectory. What led you to MedTech? [00:02:40] Maria Artunduaga: Sure. So it's gonna be a little long and I'm gonna tell you everything about my life because the personal history is very important to me and for my company too. So, as you have noticed, I have an accent. So, I grew up in Columbia in a very small town in the southern part of the country. My parents were both doctors and I'm the oldest of four kids and two of us followed their lead. So my life in my city was pretty chill. Everyone knew everyone. I spent most of my days at a Catholic school studying very hard on weekends where I usually spent tagging along my parents to doctor events. One of the things that I really like to tell, it's how my parents work as entrepreneurs really shaped my life. They were real pioneers. They built in my hometown the first big clinic back in the eighties and the nineties. And my mom was the only woman in that group, and she actually was the CEO for a while, which was a big deal. She was the only woman in a partnership of 10 people. And watching them build that clinic, that hospital really taught me a lot about dealing with uncertainty and finding solutions. Every day we'll have supper or lunch and I'll just hear all of these challenges and stories, their struggles and how they solve things. Something that was, that is definitely super helpful in what I do now, right? So, and then I was 16 and after high school I moved to Bogota, the capital, which is up in the mountains, it's very cold. I got a scholarship 'cause I was always a very good student. You know, career I spent my last year, I spent nine months in the US. Honestly, coming to the US blew my mind. The technology that I got to see, the speed, effects on science, it was nothing like I've ever seen before, and that was true inspiration for me. So I knew that I had to come to the US. I needed to come back to learn from the best, of course. And it's interesting because my parents didn't want me to relocate to the US. I was the oldest. I was supposed to follow into their footsteps and obviously, like inherited that clinic, right? That hospital, we call it clinic, it's actually a hospital. And I was a very contrarian. I didn't listen to them. I told them, you know, I really wanna be where the best people are. And what I did was that I, it took me three years to save the money to come to the US, to get Harvard to actually sponsor me my visa because they wouldn't pay me for the first year. So I remember I had to save $30,000, which in pesos is significant. So back in 2007, so many years ago, I made it to Boston, and the original idea was that I wanted to become a pediatric plastic surgeon and bring that level of care back to Columbia. I spent four years of researching a genetic ear condition that's called microtia. And with that work, I was able to land a plastic surgery residency spot or position at the University of Chicago. And I shared this with a lot of people. I actually had a really negative experience. Things didn't go as planned. I actually faced discrimination. I eventually, you know, had to leave and I made the top choice to never ever go back into clinical practice. And I changed paths. I was 32 years old and yeah I decided to switch gears. I retrained into public health and tech. And then in 2016, I moved to the Bay Area where I am right now. And I got another scholarship to finish master's in translational medicine at UC Berkeley and UCSF. And during the courses that I took, some of them with business class etc., etc., I decided to found Samay in 2018. I really wanted to build something that would really make a difference in respiratory medicine. And this is where my grandmother comes. So my, the grandmother, my abuela, her name was Sylvia and she had Chronic Obstruct Pulmonary Disease or COPD and she's the reason behind my company. So, she often couldn't tell when her symptoms were getting worse. That's a huge problem. Catching the respiratory attacks, exacerbations is definitely key to keeping people outside of the hospitals, and obviously feeling their best to have a better quality of life. So, that's what we are trying to solve with a company, right? If we are able to catch those exacerbations even with a day or two notice in advance, right, that we can all make a difference. And so by missing these exacerbations, we are having really high expenses in hospitalizations and ER visits and the problem we trying to solve is that today technologies that are adequate enough to be used outside of the hospital because the ones that are considered to be the gold standard, they are very expensive. They are confined to their hospitals and they are very difficult to complete for the patient, especially when they're exacerbating. They need to blow out forcefully for about 10 seconds, 21 times. So what we are doing is, we are developing a sensor that makes it super simple for people to use it at home to track their lung function without doing those forceful maneuvers and ideally in the future to warm them, right? Like to let them know when things are starting to go south or obviously, you know, not going very well, and that's what it's all about. I mean, that's what we do with Sylvee right here. And it's wearable sensor and we have done significantly well over the past couple of years. We actually just won MedTech Innovator. [00:08:04] Lindsey Dinneen: Yeah. Significantly well over the last few years. Yes. So congratulations on that, and I want to dive into all of those exciting milestones in just a second. But I am, first of all, so inspired by your story. Thank you for just sharing that your resilience and your grit and your determination are really admirable. So thank you for sticking with something that was not easy, not an easy path. [00:08:29] Maria Artunduaga: I know. I know. [00:08:31] Lindsey Dinneen: It continues not to be, ironically, as we've kind of touched on before, but just going backward a little bit in your story. So I, it sounds to me like getting the opportunity to watch your parents have this incredible impact on their community and the healthcare and the opportunity is just so valuable for you. And even just learning about how your mom was the CEO and those kinds of things, did that help shape the idea for you that not only is entrepreneurship possible, is innovation and healthcare possible, but you can also be this in incredible leader as a woman in whatever capacity? I would just love to dive into that. [00:09:13] Maria Artunduaga: Yeah, it's super interesting, right? My mom really taught me a lot about leadership. She's a surgeon, so you can imagine how good of a leader she is in the operating room at home, everywhere, right? I mean, she's definitely the general, that's how I call her. And I honestly, I try to replicate, so my leadership and styles pretty much shaped by her. So I always call her my best role model whenever somebody asks me about the question, right? So I'm just like her. I lead from the front. I like setting the pace by working the hardest. So I really like to lead by example and I also, just like she did, and obviously because of her surgical training, I hold myself to a really high standard, and I expect everyone on my team to do the same. So people in my company know that I'm very strict, I'm very disciplined, and they know that from the beginning. It's so funny because when I interview all of them, at the final interviews with me, and I actually do the anti sale to join Samay. It's like, this is, these are all the reasons why you shouldn't join. I start describing myself as a very intense, obsessed CEO with insomnia, which I still have, because I really wanna make this work, right? So, yeah, I, ask them, and most of them say yes. I really like, I attract people that like challenges, especially intellectual challenges. So, yeah, to this point, most of them say yes. Some of them have obviously, you know, because probably too much. But at the same time, I tell them, "Look, this is going to be very hard in terms of the deliverables, the things that we're expecting from you." But at the same time, my goal is to not only help people with respiratory problems, I try to sell the company as a company where everyone that gets hired can be themselves and thrive. So, so for example, I tell them," Look, I'm trying to be the boss that I never had." And this goes obviously very tied to the very negative experience that I had during my surgical residency and even before, right? So, I never had a boss that really supported me, who recognize my true self and those characteristics as good things, right? So they always try to tone me down. I'm very energetic, as you can notice, and I'm also super ambitious. I'm really ambitious. I wanna do all of these great things. And they always thought that I was aiming for too much, especially for a woman. It's like, " You need to lean in, Maria. You need to behave." So I remember my residency, they were criticizing like, "Why are you behaving like this, Maria? Why are you asking so many questions? You're asking too many questions. You look more as an internal medicine doctor. Why are you always smiling, Maria? Why are you so happy?" So now, with everyone that I hire, what I try to do is that I focus on understanding their dreams and I try to figure out how this job is gonna help them get there. So if they wanna become a top engineer, maybe they wanna learn managerial skills, or they wanna run operations, or they eventually wanna become a founder themselves. So I try to create a partnership with them where they obviously help me succeed with the company, build Samay, but at the same time they get to do this personal growth. So it's extremely important that they get to place where they wanna be. [00:12:32] Lindsey Dinneen: Yeah, that's wonderful. And such a gift to your employees. And I also honestly, that sort of anti interview or whatever technique is brilliant because you do want it to be a fit for everyone, and it's so much better to have aligned expectations from the start. So, oh my goodness, that's so interesting. So, okay, so then. Speaking into that, how do you develop a company culture for yourself? You've learned from some pretty negative experiences, so obviously that's what not to do, but you know, as you're crafting your own company culture now, what kinds of things are sort of your core values, other than of course, your hard work and your excellence and holding yourself and others to high standards, but what kinds of things do have you developed that make it special to be where you are? [00:13:19] Maria Artunduaga: Yeah, I mean, that's a really good question. I'm very true to myself, and one of the things that I wanna do with Samay, it's I wanna create legacy. If you go to my WhatsApp, that's exactly the little logo or the slogan that's below my name: I'm creating or building my life's legacy. That's how I pitch myself. So I really wanna be remembered as someone that made healthcare more accessible, especially for the people that get left behind. So growing up in Columbia, I saw firsthand how unfair things will be and I wanted to change that. So that's how the values of Samay go, people first. I think legacy, it's extremely important, right? It's about getting those life changing tools and opportunities into the hands of people who really need them. And again, it's not necessarily, the group that we're building. It's the own experience of building a company with me, learning from the company, from the people that are working with. I really wanna make it accessible for people. And I wanna also be obviously a source of inspiration. You don't necessarily need to be this perfect person to be a CEO. You know, life is a struggle and that's totally fine. Just be very passionate about building legacy, right, your work and how you're impacting other people. And especially for me, I do a lot of work with women and minorities. I really wanna empower them to chase their dreams in science and technology. I really care about people. I don't know, I'm selfless about me. It's all about the others and creating legacy and being remembered. So, yeah, that's how I, that's how I roll. [00:14:59] Lindsey Dinneen: I love that. I love that. So speaking of you embracing the CEO role, when you first started your company, did you feel ready to step into this kind of position? Or was it something where you just were like, "You know what? I see the need. I know I can make a difference in this field. I'm gonna do it and I'll learn along the way." [00:15:19] Maria Artunduaga: No, not at all. And let, so there's a very good anecdote that I'm sharing. Again, back to all of these life changing experiences. I got into medtech because of, I don't know, somehow the planets got aligned, right? So I was doing a master's in public health because I thought that was going to be my real call, working for Gates in Seattle, because that's where I actually lived for about two years. Then I came to realize that it was very bureaucratic. It's very, was very slow. I have a type A personality. I really like to fix things very quick. I like to implement stuff. So I decided to do a second master's degree, and as I mentioned, here in Berkeley, I decided to join one of Atma METs minority programs for students, right? It's called SMDP. And I remember that was back in 2016, and they sent me to Minneapolis for the big conference. And that's where I got my first real taste of MedTech. And I remember watching the MedTech Innovator finals with Paul Grand. He was introducing the program, the finalist. I remember clearly seeing all of his pitches and how Green Sun Medical CEO won, and it was a game changer to me because when I saw them pitch, it was very exciting. You know, all these technologies, the many millions of people they could definitely impact, I saw that, and it clicked. I could turn the scientific ideas into something that helps millions in a way, the way how I would practice medicine, but in a more impactful way. So interesting story though. So the other thing that was very inspiring or at least that motivated me, I was the only person in the room who looked like me and spoke with an accent from South America, from Latin America. So it was like two reasons behind it. For me, it was I wanna be a medtech entrepreneur, but at the same time I wanna be able to break the glass ceiling, right? The first Latina physician CEO building a company that has hardware, software, and AI, this is what we actually do. And yeah, so it, it's mainly that. I really like challenges and I'm very motivated to show people that I can do things that might seem impossible or too difficult. So I really like showing people that anything is possible with a lot of hard work and determination. So yeah, that's mainly it. [00:17:47] Lindsey Dinneen: I love that. Embracing those challenges, running full steam at them and having that, I don't know, that gumption is fantastic too. And the desire, like... [00:17:57] Maria Artunduaga: Thank you. [00:17:57] Lindsey Dinneen: ...you said, to break through those ceilings and to represent and say, "No, it is possible." It is, and I love that. So, excellent. Okay, so can you share a little bit about the journey that the company has gone under recently and some of the really exciting milestones? I know there have been bumps and whatnot, but maybe some of the exciting things that have been developing and what you're looking forward to as you continue down the road. [00:18:24] Maria Artunduaga: Sure. I mean, whew. There are so many things that have been happening for the last couple of months. So it's been a long journey. It's been six years so far. Initially, you know, I wanted to build a company with an idea that was inspired, obviously, by the fact that I lost my grandmother to exacerbation and also because, at the time, I didn't know what I wanted to build. When I was doing an interview with a pulmonologist, what I realized was that I could actually build a technology that could be inspired by consumer devices, so hearing aids for example. And funny story is that my husband who is also Columbian, and went to MIT, he's been working at Google for over a decade and he's an auto engineer. He does a lot of things. He's very smart and he's one of the main architects. What I decided to do back then was, let's repurpose hearing aid technology by sending signals through the chest, and let's use the physical principle of acoustic resonance to understand what's going on inside of the lungs. And that's exactly what we are doing. We have 10 granted patents so far. We have 20 more pending on pulmonary so far. So we've done a lot of things. So we've tested that device on 450 people almost. All of our numbers of accuracy are over 90. Sensitivities and specificities are also between 82 to 98. Right now we are starting to see changes a few days before an exacerbation is actually diagnosed by a physician, which is extremely exciting. We have data from two people. Obviously it's a small sample size. We are following eight of them, and we're aiming to finish at 60 to hundred people in the next year or so. So that's our main goal. We've raised 5.2 million, 60% of that money is coming from grants, federal grants, and we just submitted a breakthrough designation to the FDA about a week ago, so fingers crossed, though, we get it right? There are a lot of things in the pipeline, things that are very exciting. Right now I'm super excited 'cause those six years were very hard. I was running a science project with my nails, getting money from grants, help from people who have known me forever. It was very hard for me to recruit a full-time CTO. So my husband has been helping me with some hours here and there. And we have right now 12 people in Columbia. So for developers, designers, clinical researchers, we are running most of our operations in Latin America because it's extremely, well, obviously cost efficient, and more importantly, we have access to people that are patients especially that are, that exacerbate more often. So we are to leverage all the different angles that we can get. [00:21:04] Lindsey Dinneen: Yeah. Wow. So lots of exciting things in the works and in the future, and oh my goodness, I'm so excited, can't wait to continue to celebrate all those wonderful accomplishments. So I'm curious, as you've taken this journey and even before with your other health experiences and finding this path, are there any moments all along the journey that really stand out to you as affirming, "Yes, I am in the right place at the right time, in the right industry." [00:21:31] Maria Artunduaga: Yeah, beyond the MedTech Innovator, the experience eight years ago, I mean, every day I find that this is the perfect fit for me. I always tell people, "Look, entrepreneurship is not for everyone. It really needs to be a fit of personality." So when I talked to my parents, because at the beginning they weren't very agreeable with the idea of me becoming an entrepreneur 'cause physicians don't do this, right? I was sort of like a black sheep of a family, 'cause my sister, she's successful and she's a pediatric radiologist as she's working for an academic center in, in Dallas. So, my personality, I'm Type A. I'm very anxious. I really like doing things super fast. I really like to get things done, right? So, I dunno if I picked the wrong career, probably could have done a better job as an engineer, as a scientist myself. So at heart, I'm a true scientist. That's what I really enjoy. I like practicing medicine, sort of miss it a little bit, but I'm more in the quest of solving questions and discovering, right? That's what really excites me. And then, every day is a new day when you're building a company. And the challenges that I have every day, all of the problems I have to solve, I really enjoy the process of solving them. And this is a little crazy. Who gets excited with problems, right? So, I don't know, that's probably me. So I guess every day, the moment I go home or that I go to sleep, I say, "This is perfect. I don't think I'll be as happy as I am right now if I had stayed medicine. I don't think so." [00:23:10] Lindsey Dinneen: Wow. And that says a lot. And that just affirms to you on a daily basis, "Yeah. I am doing what I'm supposed to be doing. That's wonderful. [00:23:17] Maria Artunduaga: Exactly. Right. It's like, yeah, I'm good at this thing. You know? I like solving problems. I got, I really enjoy the fires. I really like them. I's like, I don't know. I'm, yeah. I'm addicted to them. [00:23:30] Lindsey Dinneen: I love that. Well, and that is unusual, and I'm curious, do you? But it's a great thing. No, it's a wonderful thing. Yeah, no, absolutely. I love that. So, so when you're at finding yourself up against a problem, do you start with any particular kind of established framework? Do you like to just brainstorm solutions? How do you approach problem solving? [00:23:53] Maria Artunduaga: Gosh, this is a really good question. It's like, you know, if I had to teach something, right? So I'm very good at solving problems, at connecting different disciplines, right, to solve those issues. So for example, the way how I go about them, first of all, I don't get frustrated or too anxious about it. I always try to think first, right? And then, yeah, I start brainstorming. I'm very quick at thinking, my mind goes super quick. I have a whiteboard right behind me. I do a lot brainstorming on my own. I ask a lot of questions too. So I rely on a lot of people, and I get a lot of feedback on the way, how I think a problem needs to be solved. And obviously with time and experience, the older that you get, the better you become, right? So yeah, honestly, every problem is different. I just like seeing it from different angles, right? I'm very good with social stuff. I'm very good with arts too. I really like doing science, learning a about engineering. I really like different ways of solving problems. For example, I remember that I we had this NIH grant and we were working collaboration with a big, famous academic center right here. And things weren't working very well. That was through during a pandemic and I was getting charged things that we actually didn't approve. So things were getting a little awkward. I decided to finalize that agreement. But then I got through this situation that I had no access to patients here in the States, and at the time, I didn't have my clinical site in Columbia opened up. So what I did was the craziest thing, which is what I did, was that I bought an $80,000 machine and I came into an agreement with a friend from medical school who has a pulmonary practice in South Florida, one of the largest pulmonary practices. He's a partner with nine other guys, and they see probably a hundred patients every day. Can you imagine that? So respiratory patients, and I told him, "Look, I don't have any money to pay your rent, but I'm gonna give you equity for that rent, and you're gonna use this machine from Monday through Thursday, and I'm going to test your patients from Friday to Saturday. And I'm going to bring people, I'm going to become my own CRO, right? So I'm gonna bring people, doctors, from Columbia on a J1 visa as a research scholar visa. I'm gonna train them and I'm gonna get them to do the recruitment, review everything, test the patients. We are going to become our own CROs, and we are going to do as many people as we can every single week." So we were able to do 430 people in a span of a probably a year and a half. Something that usually would cost us thousands of dollars. I dunno how much money I spend, probably just 300,000 to do everything. Can you imagine? I mean, that's significantly cheap compared to any other quote that I've been getting from an academic center. So, I sometimes go for the crazy idea, right? Like, what's the craziest thing that I could think of? I literally, I write it down, right? And then I just try to double check with my lawyer. "Am I doing something illegal here?" And I, yeah, I cross reference with other founders. " I'm thinking of doing this, how that's that sound?" And they're like, "This is pretty non-traditional, Maria, but I mean, if you can get it done..." I'm like, "Yeah, of course I can get it done." And I just get it done. I just don't take a no for an answer. I'm very good at also finding, convincing people to jump on board with the vision, the mission. This excitement, this energy, people really get very engaged with Samay and with me as a founder, and they love it. Most of these people either have invested in the company, they are helping me many more hours, pro bono, literally free, and we are building together. [00:27:43] Lindsey Dinneen: Wow, that is so cool. And what a fantastic story. Thank you for sharing that one as well. Oh my word. [00:27:50] Maria Artunduaga: I have way too many stories to share. This is the one I really like to, to tell people. [00:27:55] Lindsey Dinneen: I love that, and I love the willingness to come up with those crazy ideas. And it might be just so crazy that it works. So, hey, you never know until you try, and that's fantastic. Oh my gosh, I love that approach. Alright, so pivoting the conversation a little bit just for fun. Imagine you are to be offered a million dollars to teach a masterclass... I know! ...to teach a masterclass on anything you want. What would you choose to teach? [00:28:22] Maria Artunduaga: Yeah. So, good question. So, gosh, I, I tackle problem. So my, my brain again is very good at figuring stuff out. That plus the fact that I'm very stubborn. So if I'm into something, I don't give up easily. And now I'm gonna tell the story about our winning MedTech Innovator. We beat 65 companies globally, right? And I still like, sort of, I cannot process that we won. So the story goes like this, but a year ago, I tried to raise five millions, my very first institutional round, and I totally flopped. [00:28:55] Lindsey Dinneen: Oh. [00:28:56] Maria Artunduaga: I only got $200,000 because multiple funds that I was talking to, they wanted me to feel half of the round before weighing any money or signing anything. So you can imagine. So do I got, you know, chicken or the egg problem? I failed. And instead of crying or mopping, I thought, "Okay, wait. I got into Medtech Innovator. You know what? I'm just gonna win that competition, still $350,000." And why not? So obviously people, my advisors, my best friend, "Like, you're crazy. It's the most competitive thing ever. You're not established in the field. People know who you are, but it's not like you have exited a company or anything, right? You're not even an engineer, Maria." So what I did was, again I went back to my whiteboard. Again, I probably should have become an engineer before, I dunno. I'm really good at solving problems. So I was like, "You know, this is a problem. These are the different ways how I can tackle this." And more importantly, I'm very good at the studying stuff. I really like, again, knowing, wisdom, information. I just love that. I really love that. So what I did was, I treat it like a big project, and I talked to the past winners, anyone who had done or won any sort of like prize with MedTech Innovator, and I figure out their secret sauce. So I either talk to them, I studied every single video, every single pitch. I spend many hours studying everyone who had one or had done significantly well throughout the accelerator. So what I discovered was the accelerator was kind of a school, like a school. So the harder you work, the better you do. And one of the things that I realized was that mentors and reviewers were key players. So I focused on building those connections. I met with many of them. I probably spent about, I don't know, probably four to five hours meeting with mentors, anyone who I thought could help me somehow, obviously, for free, because a lot of the help that they give used for free. And I also spent a lot of time doing homework, the webinars, et cetera, et cetera. I ask a lot of people for advice. I really got people excited about Samay. I recruited my mentors and they got on board from day one. Because of that, I started building those relationships and it was authentic. I mean, don't get me wrong, this wasn't like, you know, I'm trying to play anybody. I really care about what they had to say, and I incorporate all that feedback into my company to this day. So the other thing is, I make sure to go to everywhere, every webinar, every event, everything. My camera was always on, because most people, when they do their webinars, they don't even turn on their cameras, right? So I was very engaged. I was asking questions, I was getting involved with everything. Same thing with the Slack channel that we have for MedTech Innovator. I was helping people, I was sharing stuff. I was even offering to make introductions. I really made sure that people knew who I was. And I obviously also asked the MedTech Innovator people, the staff, for help, feedback, right? Am I doing this right? What do you think I should do? Anything that you can share with me that you think. I was very clear with them. I wanna go to the, I wanna get to the finals. I told them, and I remember they telling me, "Oh, Maria, about getting to the finals, it's so hard. It depends on the strategics and the sponsors." And I was like, " I'm gonna get there. What do you think I should do?" So I literally ask a lot of people how I needed to get there. And with the finals, the way how they pick the finalist, it's actually the mentors who go in front of the strategics, and they sort of champion your company. And they really went to bat for us. They told them how committed I was, the many people that from my team were actually going for participating to the winner because I brought people from my team... [00:32:45] Lindsey Dinneen: Yeah. [00:32:46] Maria Artunduaga: You know, very few founders did that. I brought people from Colombia, obviously online, people who barely could understand English. But, I made them prepare questions. "You need to do this and that we need to be super engaged. We need to help other people." And they saw it was hard work. And at the end, we got into the finals and what I realized was, okay, so after the finals, I understood that the game was, obviously it changed. The way how the winner is chosen is that the audience votes, right, during The MedTech Conference. So what I did was, I went all in on social media. We made an awesome video for the best video competition. I remember that that was the first thing that I did back in June. I scheduled two weeks. I flew to Columbia. I hired right people. I made sure that I was perfect, so I was part of the creative team. I designed everything. Again, I really like arts, right? That's why, one of the reasons why I didn't, I was in pleasantry and that's why I really like dancing too, right? So I'm obsessive with everything that we do. I really am into the details and I supervise everything. And we also got into the finals for the best video competition. So I was going to this problem from every single angle. I didn't let anything up to chance. I, yeah, I'm a freak. I'm a control freak. That's what I did. I remember that even for the pitch, the four and a half minute pitch, I practiced, I don't know how many hours, but every single thing that I say that was obviously memorized, needed to be perfect. The way how I, let's go back to dancing since you're a dancer yourself, the way how I moved my hands, right? The way, how I walked on that stage, everything was rehearsed. So, yeah, I mean, I just I worked my ass off. I mean, everything was the way it needed to be and that's how we won. [00:34:39] Lindsey Dinneen: Yeah. Wow. That's great. What a fantastic story. Yeah. Amazing. Yes. I love how it's so choreographed. Yeah, that's [00:34:48] Maria Artunduaga: great. It was choreographed, [00:34:50] Lindsey Dinneen: I love that. Excellent. Well, I know you have touched on the importance of legacy and how much that means to you, but how do you wish to be remembered after you leave this world? [00:35:03] Maria Artunduaga: Oh gosh. Yeah. I mean, so I have a little daughter, I want to some somehow replicate the same experience that I had with my mom. Maybe she doesn't even realize how much of the inspiration and the impact that she had on me. And again, leading by example, I don't spend a lot of hours with my daughter, right? I have a nanny for 12 hours. So my salary goes to her payment, right? Yeah, I wanna be remembered as somebody who tried very hard, who literally, instead of saying things, I walked the talk. The things that I said I was going to say. For example, I'm very opinionated with anything diversity and inclusion because, as I've said, I've experienced discrimination myself. So I walk the talk, I build a product, I build the change. I worked really hard. I impacted a lot of people. And more importantly, the world has changed somehow because I existed. So that's that. It's as simple as that. I wanna help other people get to fulfillment of their lives and their dreams. And yeah, and I obviously wanna be happy while I do all of these things. And more importantly, I wanna feel that I learned a lot. I really like learning. The process of learning every single day, learning a new thing makes me super happy. So if I don't learn something new, I consider day as, you know, as like a flop or something. So yeah, it's very simple. I'm actually a very simple person, I'm not that complicated. [00:36:30] Lindsey Dinneen: Yeah. Okay. And then final question. What is one thing that makes you smile every time you see or think about it? [00:36:39] Maria Artunduaga: Oh, cute. I mean, obviously my daughter. So I'm a mom. I'm 44, well, almost 45, and I had her at 42. So just thinking about her makes me smile every single time. She's a miracle baby. She's, you know, after four years of IVF, eight retrievals, it finally happened. I finally had her, and having her in my life has turned my world upside down in the best way. She's determined, and she's only three. She's diving into doing all sorts of things. She's doing gymnastics, she's building Legos, she's doing engineering stuff. I really like that "I can do anything attitude" and obviously I'm sort of like reinforcing her to do anything she wants to try. So seeing her try all these new things, all this confidence that I, that she has. It's like, I don't know. I mean, that inspires me. That motivates me to be a better mom, a better CEO, and to do exactly the same thing with the people that I work with. So everyone in my company, I I tell them I'm a mom, right? So, remember that, and I try to do the same with them. It's like I tell them, what do you wanna do? What do you wanna learn this month? What do you need? Right? My work as a CEO is getting the resources and put out the fires. Just tell me, and this is your playground, so I'm trying to do exactly the same with my daughter too. But yeah, I'm very happy with her. [00:38:07] Lindsey Dinneen: Aw, that's wonderful. I'm so glad. Well, oh my goodness, this conversation has been amazing. I kind of wish it didn't have to end, but I also wanna respect your time 'cause obviously you have so much going on. But thank you so much for sharing about your story, your advice. You're so inspiring, and I know this is gonna inspire so many people to go for it, and not to have the fear, to have that problem solving mentality, and growth mindset and learning and, hey, look where curiosity got you. [00:38:37] Maria Artunduaga: Yeah, exactly. That's a perfect slogan. It's all about that curiosity and it gets you places. Look at me. [00:38:43] Lindsey Dinneen: Yeah, exactly. Yeah. And this is just the start. [00:38:47] Maria Artunduaga: Yes, of course. [00:38:48] Lindsey Dinneen: Indeed. So I just wanna say thank you again for your time today, and we just wish you the most continued success as you work to change lives for a better world. [00:38:58] Maria Artunduaga: Thank you so much and thank you again for invitation. I really enjoyed it. [00:39:02] Lindsey Dinneen: Yeah, absolutely. Me too. And we are honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. We really appreciate you choosing that organization to support and thank you just again, so very much for your time here today. Yeah, and holy cannoli, thank you so much to our listeners for tuning in, and if you're feeling as inspired as I am right now, I'd love it if you'd share this episode with a colleague or two, and we'll catch you next time. [00:39:44] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

Story at-a-glance People managing multiple chronic illnesses are nearly twice as likely to develop depression, even if they've never had mental health issues before, according to a decade-long study Living with both heart disease and diabetes drastically increases your future depression risk, making cardiometabolic combinations among the most dangerous for emotional health outcomes Chronic illnesses like asthma, chronic obstructive pulmonary disease (COPD), liver disease, and bowel disorders sharply increase your risk of depression by overwhelming your body's ability to regulate mood and energy Women with joint and bone issues like arthritis face a higher depression risk than men with the same diagnosis, revealing a serious and often ignored gender vulnerability Depression doesn't just follow disease — it drives it. Left untreated, it speeds up illness progression, weakens your immune system, and increases your chances of hospitalization

Story at-a-glance People managing multiple chronic illnesses are nearly twice as likely to develop depression, even if they've never had mental health issues before, according to a decade-long study Living with both heart disease and diabetes drastically increases your future depression risk, making cardiometabolic combinations among the most dangerous for emotional health outcomes Chronic illnesses like asthma, chronic obstructive pulmonary disease (COPD), liver disease, and bowel disorders sharply increase your risk of depression by overwhelming your body's ability to regulate mood and energy Women with joint and bone issues like arthritis face a higher depression risk than men with the same diagnosis, revealing a serious and often ignored gender vulnerability Depression doesn't just follow disease — it drives it. Left untreated, it speeds up illness progression, weakens your immune system, and increases your chances of hospitalization

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Sly Stone dying after a prolonged battle with COPD, if he’s concerned about the ability to get flu shots this fall, and to share his thoughts on Robert F. Kennedy Jr. removing the 17 independent vaccine experts from the […]

Continuing our series on What You May Have Missed at ATS 2025, host Amy Attaway, MD, MS, of Cleveland Clinic, dives into key topics from the Clinical Year in Review with Sara Auld, MD, MSc, Emory University. Did you miss the ATS 2025 International Conference? Or were you unable to attend some key sessions? Go to conference.thoracic.org/program/conference-highlights/ to purchase your ATS Conference Highlight Package. 

一、【20250607間菩提】 慈濟將近六十年了，腳步是一步步地向前走，但方向不可以偏。所以面對著人間事相，慈濟都很謹慎在做，從沒想過能得到什麼。如何去為人間付出，對社會有益，我們該做，總是去做。 因為做慈善，看見了老、病、苦，所以開始義診，而且不只是治療，還要關心他們以後生活怎麼過，在因緣範圍裡，做得到的，盡量去做。但個人的力量有限，所以需要各行各業一起投入，利益人間。 空間、人間，合起來就是世間。人在這個大空間裡如何能和平相處，就是要人人和合。方向正確，就是永恆的和平，宗教就是希望這樣。輔導人、淨化人心，去除偏差的惡念，往善的方向去利益人間，所有的宗教總是止惡揚善，是共通的道理。 二、健康100分 花蓮慈濟醫院的「肺部守門員」劉迪塑醫師，深入探討慢性阻塞性肺病（COPD），這是國人十大死因之一，尤其抽菸族群為高風險群。劉醫師指出，肺阻塞屬於退化性疾病，肺功能一旦受損便無法逆轉，且退化速度可能為正常人的兩倍，因此強調「及早預防」的重要性。 他呼籲民眾戒菸與遠離空汙，包括二手菸與環境廢氣，同時建議每週至少進行150分鐘中等強度運動，如快走、慢跑、超慢跑、爬樓梯等皆可分段完成，達成提升心肺功能的目的。對於已有症狀者，劉醫師推薦「噘嘴式呼吸」與「腹式呼吸」兩種技巧，能減緩呼吸困難、強化自律神經、改善生活品質。 除了運動與呼吸訓練，劉醫師也提及疫苗施打的重要性，特別是65歲以上長者與慢性病患者應接種肺炎鏈球菌疫苗與流感疫苗，以減少肺部感染與急性發作風險。此外，營養攝取同樣關鍵，肺阻塞病人常因喘促而影響食慾，建議採少量多餐、軟質飲食、補充高蛋白，預防營養不良與肌少症。 最後他提醒，COPD患者常伴隨多重共病，如肺癌、憂鬱症與心血管疾病，故需全面照護。唯有從自身生活方式著手，包含戒菸、運動、飲食、疫苗與情緒管理，才能達到長期穩定控制與健康生活的目標。

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Sly Stone dying after a prolonged battle with COPD, if he’s concerned about the ability to get flu shots this fall, and to share his thoughts on Robert F. Kennedy Jr. removing the 17 independent vaccine experts from the […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Sly Stone dying after a prolonged battle with COPD, if he’s concerned about the ability to get flu shots this fall, and to share his thoughts on Robert F. Kennedy Jr. removing the 17 independent vaccine experts from the […]

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-436 Overview: Many patients with chronic obstructive pulmonary disease (COPD) are improperly treated with inhaled corticosteroids (ICS), increasing their risk of harm. This episode explores the latest evidence on long-term ICS risks and provides practical guidance to help you align COPD care with current guidelines—improving outcomes while minimizing adverse effects like pneumonia, cataracts, type 2 diabetes mellitus, and osteoporosis. Episode resource links: Pace WD, Callen E, Gaona-Villarreal G, Shaikh A, Yawn BP. Adverse outcomes associated with inhaled corticosteroid use in individuals with chronic obstructive pulmonary disease. Ann Fam Med. 2025;23(2):127-135. doi:10.1370/afm.240030 Pocket Guide to COPD Diagnosis, Management, and Prevention: A Guide for Healthcare Professionals. 2025 Edition. Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org/2025-gold-report/ Guest: Jillian Joseph, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-436 Overview: Many patients with chronic obstructive pulmonary disease (COPD) are improperly treated with inhaled corticosteroids (ICS), increasing their risk of harm. This episode explores the latest evidence on long-term ICS risks and provides practical guidance to help you align COPD care with current guidelines—improving outcomes while minimizing adverse effects like pneumonia, cataracts, type 2 diabetes mellitus, and osteoporosis. Episode resource links: Pace WD, Callen E, Gaona-Villarreal G, Shaikh A, Yawn BP. Adverse outcomes associated with inhaled corticosteroid use in individuals with chronic obstructive pulmonary disease. Ann Fam Med. 2025;23(2):127-135. doi:10.1370/afm.240030 Pocket Guide to COPD Diagnosis, Management, and Prevention: A Guide for Healthcare Professionals. 2025 Edition. Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org/2025-gold-report/ Guest: Jillian Joseph, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

Grab your earphones! Get ready to listen and learn!

Story at-a-glance Research shows perceived stress significantly worsens COPD symptoms, with high stress levels quadrupling the risk of serious flare-ups requiring medical intervention Stress triggers biological changes in COPD patients, increasing inflammation markers and oxidative stress that directly damage lung tissue and impair breathing People with COPD who experience high stress levels report greater death anxiety, especially women, unemployed individuals and those lacking education about their condition Understanding your condition and building confidence in managing symptoms (self-efficacy) significantly reduces both stress levels and physical complications of COPD Simple interventions like focused breathing, symptom tracking and establishing daily routines help interrupt the stress-symptom cycle and improve quality of life

This week, Dr. Kahn dives into a packed lineup of new research and hot topics in heart health. He breaks down two major U.S. government reports—one on vaccines and another on the #MAHA movement—before covering a wide range of updates, including: plant-based diets and fasting-mimicking diets for liver health, high-fiber diets and PFAS, vitamin D and aging, CoQ10 and Fosamax, creatine for brain health, conflicts of interest in meat studies, HRT and heart markers, Type 1 diabetes and plant diets, homocysteine in hypertension, mouth taping, niacin in COPD, and aspirin use based on coronary calcium scores. The featured segment tackles the controversy around seed oils—often labeled the “Hateful 8.” Are these oils really harming your health, or is the fear overblown? Dr. Kahn breaks it all down in this must-hear episode.  Thanks to endur.com – use the code KahnMD10 for a discount.

Leah breaks down everything veterans need to know about getting VA disability benefits for COPD (Chronic Obstructive Pulmonary Disease). She explains how COPD includes conditions like chronic bronchitis and emphysema, outlines symptoms, and dives into medical literature showing a strong connection between toxic military exposures (like burn pits or Agent Orange) and COPD—even in non-smokers. Leah details the VA rating system, diagnostic codes, necessary medical documentation (like pulmonary function tests), and strategies for building a strong claim. She also clarifies how COPD can be service-connected directly, secondarily, or presumptively, and encourages veterans to seek help from VSOs or accredited representatives if they've been denied.

Contributor: Travis Barlock, MD Educational Pearls: Wheezing is classically heard in asthma and COPD, but it can be the result of a wide range of processes that cause airflow limitation Narrowed bronchioles lead to turbulent airflow → creates the wheezing Crackles (rales) suggest pulmonary edema which is often due to heart failure Approximately 35% of heart failure patients have bronchial edema, which can also produce wheezing COPD and heart failure can coexist in a patient, and both of these diseases can cause wheezing It's vital to differentiate whether the wheezing is due to the patient's COPD or their heart failure because the treatment differs Diagnosing wheezing due to heart failure (cardiac asthma): Symptoms: orthopnea, paroxysmal nocturnal dyspnea Diagnostic tools: bedside ultrasound Treatment: diuresis and BiPAP for respiratory support Not all wheezing is asthma Consider heart failure in the differential and tailor treatment accordingly References 1. Buckner K. Cardiac asthma. Immunol Allergy Clin North Am. 2013 Feb;33(1):35-44. doi: 10.1016/j.iac.2012.10.012. Epub 2012 Dec 23. PMID: 23337063. 2. Hollingsworth HM. Wheezing and stridor. Clin Chest Med. 1987 Jun;8(2):231-40. PMID: 3304813. Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode 287, which is one of my all-time favorite episodes. And that's because it completely debunks some things I (and many students) are taught in nursing school. I learned a ton creating this episode, still re-listen to it on occasion, and hope you find it just as valuable, too! In nursing school, I learned that digital clubbing was a key sign of COPD and I accepted this as gospel and moved on with my life. I used this information to answer exam questions on the topic and I always included assessing for it in my care plans for patients with COPD. But, like all things in nursing, there's so much more to this story. In this episode you'll learn why much of what you've been taught about digital clubbing is wrong, and what's actually going on (spoiler alert…we don't fully know!) In this episode, you'll get answers to your burning questions: What is digital clubbing? What disease conditions are associated with digital clubbing? How is digital clubbing evaluated, measured and categorized? What is the pathophysiology of digital clubbing? ___________________ Full Transcript - Read the article and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Study Sesh - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  Med Surg Solution - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides.  Clinical Success Pack - One of the best ways to fast-track your clinical learning is having the right tools. This pack includes report sheets, sheets to help you plan your day, a clinical debrief form, and a patient safety cheat sheet.